Regulus Reports First Quarter 2017 Financial Results and Corporate Restructuring
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Buildings collapse as quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Regulus Therapeutics (RGLS) Misses Q1 EPS by 3c, Announces Workforce Reduction; CEO to Resign
May 4, 2017 4:33 PM EDTRegulus Therapeutics (NASDAQ: RGLS) reported Q1 EPS of ($0.38), $0.03 worse than the analyst estimate of ($0.35).
The Company also announced a corporate restructuring plan to streamline its operations as it focuses on its most promising discovery and development programs.
The restructuring includes an immediate workforce reduction of approximately 30%, which is expected to result in approximately $6.0 million in annual... More
